Abeona Therapeutics Inc. · NASDAQ:ABEO
Abeona Therapeutics — H.C. Wainwright 28th Annual Global Investment Conference (September 2026)
19 slides from Abeona Therapeutics's conference presentation, Sep 15, 2026
Slide 1: H.C. Wainwright 28th Annual Global Investment Conference
“Gig Abeone THERAPEUTICS H.C. Wainwright 28th Annual Global Investment Conference September 15, 2026
Slide 2: Forward-looking statements
Forward-looking statements This presentation contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties. We have attempt
Slide 3: Abeona is a commercial-stage cell and gene therapy company
Abeona is a commercial-stage cell and gene therapy company —— zevaskyn° (prademagene zamikeracel) gene-motifed cellar sheets PRECLINICAL PHASE 1/2 PHASE 3 / PIVOTAL ‘APPROVED PSMA-SIR-T* Advanced Prostate Cancer a w 4 wi Zz é- & < a Ux111** ‘Sanfilippo syndrome type A (MPS IIIA) PDUFA Sep 19, 2026 S
Slide 4: ZEVASKYN adoption sets foundation for Abeona's growth
ZEVASKYN® adoption sets foundation for Abeona’s growth Q2 2026 Highlights Net Product Revenue ($M) Growing Qualified Treatment Center (QTC) network across U.S. 0 Sue is home to 40% of addressable market. High unmet need in RDEB with growing interest in ZEVASKYN: 100+ patients have been identified ac
Slide 5: RDEB is caused by lack of functional C7 protein, resulting in large, chronic wounds
RDEB is caused by lack of functional C7 protein, resulting in large, chronic wounds * Rare and debilitating condition caused by mutations in both copies of COL7A1 gene ° RDEB wounds can lead to serious life-threatening complications — Years of large painful wounds, itch and infection — 90% risk of d
Slide 6: ZEVASKYN (prademagene zamikeracel)
(prademagene zamikeracel) "| Geovanna, a ZEVASKYN?® patient at age 8
Slide 7: Up to 12 ZEVASKYN sheets can be applied in one surgical session
Up to 12 ZEVASKYN sheets can be applied in one surgical session | ZEVASKYN sheets can be joined together to treat larger Two pea-sized wounds on patient's front, back, or sides, (8 mm) biopsies or used individually for smaller wounds ZEVASKYN cellular sheet Up to 12 ZEVASKYN sheets ADULT with RDEB C
Slide 8: Example RDEB wounds before and after ZEVASKYN treatment
Example RDEB wounds before and after ZEVASKYN treatment BEFORE AFTER ZEVASKYN BEFORE AFTER ZEVASKYN Left thigh
Slide 9: EB patients already travel significant distances for specialized care
EB patients already travel significant distances for specialized care and have indicated willingness to travel for ZEVASKYN Referral Catchment Areas For Key EB COEs (2022-2023) ene nes oat 7% of referral oO (pen aa tind S=? 30% of referrals * Roughly 40% of pts managed at EB COEs live out of state *
Slide 10: Expanding ZEVASKYN QTC network enhances patient access
Expanding ZEVASKYN QTC network enhances patient access NewYork-Presbyterian/ Columbia University Ann & Robert H. Lurie Irving Medical Center Children’s Hospital of Chicago e Stanford Medicine Children's Health e C) e Children’s Hospital of Philadelphia e e 2 Children's Hospital cincinnati chiaren a)
Slide 11: ZEVASKYN patient journey
ZEVASKYN patient journey no ovffro So Financial Hospital stay & clearance & discharge scheduling Patient identify & ZEVASKYN consult/decision Revenue recognized \ Jere Average 3-4 months ~25 days (variable and dependent on patient/site/payer considerations)
Slide 12: Example of wound healing from Phase 1/2a long term follow up
Example of wound healing from Phase 1/2a long term follow up Upper Back Patient during long term follow Patient at end of in-person Patient before treatment Patient after surgery up—year 2 long term follow up — year 5 Allimages shown are from the same patient; Individual results may vary. Study Desi
Slide 13: Distal Right Forearm
Distal Right Forearm Allimages shown are from the same patient; Individual results may vary.
Slide 14: Right Deltoid Shoulder
Right Deltoid Shoulder Allimages shown are from the same patient; Individual results may vary.
Slide 15: Examples of wound healing at years 2 and 5 for Phase 1/2a patients
Examples of wound healing at 5 years for Phase 3 patients Basoline Wound #: | pay.26 to Day Year2 Year5 “4 | Location Subject #1 | Right Upper Arm | Subject #2 Loft Leg, Anterior Subject #3 Loft Thien Individual results may vary
Slide 16: Significant U.S. commercial opportunity for ZEVASKYN
Significant U.S. commercial opportunity for ZEVASKYN ~1,300 U.S. DEB patients"; ~750 RDEB ZEVASKYN-eligible patients Anticipate average 2 treatment cycles per patient to cover impacted body areas (~1,500 treatment opportunities) $3.1M WAC per each treatment Strong payer adoption and reimbur with 98%
Slide 17: PSMA SIR-T for Advanced Prostate Cancer
Slide 18: PSMA SIR-T (ABO-701) has the potential to unlock cell therapy for prostate cancer patients
PSMA SIR-T™ (ABO-701) has the potential to unlock cell therapy for prostate cancer patients with a high unmet need * PSMAis a validated target in prostate cancer, but CAR-Ts and other immunotherapies targeting PSMA have failed to deliver durable efficacy and acceptable safety profiles PSMA SIR-T™ is
Slide 19: Significant support of ZEVASKYN and pipeline solid tumor oncology PSMA program
4 ~ Significant support $11.4M net product Pipeline solid tumor} of ZEVASKYN from revenue in Q2 2026, oncology PSMA RDEB community 31% quarter-over- program represents a and commercial quarter increase multi-billion-dollar launch on positive opportunity trajectory